-
- Claudio Scafoglio
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-6948;
-
- Bruce A. Hirayama
- Department of Physiology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1751;
-
- Vladimir Kepe
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-6948;
-
- Jie Liu
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-6948;
-
- Chiara Ghezzi
- Department of Physiology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1751;
-
- Nagichettiar Satyamurthy
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-6948;
-
- Neda A. Moatamed
- Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095;
-
- Jiaoti Huang
- Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095;
-
- Hermann Koepsell
- Institute for Anatomy and Cell Biology, University of Würzburg, 97070 Würzburg, Germany
-
- Jorge R. Barrio
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-6948;
-
- Ernest M. Wright
- Department of Physiology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1751;
書誌事項
- 公開日
- 2015-07-13
- 権利情報
-
- http://www.pnas.org/site/misc/userlicense.xhtml
- DOI
-
- 10.1073/pnas.1511698112
- 公開者
- Proceedings of the National Academy of Sciences
この論文をさがす
説明
<jats:title>Significance</jats:title> <jats:p> Cancers require high amounts of glucose to grow and survive, and dogma is that uptake is facilitated by passive glucose transporters (GLUTs). We have identified a new mechanism to import glucose into pancreatic and prostate cancer cells, namely active glucose transport mediated by sodium-dependent glucose transporters (SGLTs). This means that the specific radioactive imaging probe for SGLTs, α-methyl-4-deoxy-4-[ <jats:sup>18</jats:sup> F]fluoro- <jats:sc>d</jats:sc> -glucopyranoside, may be used along with positron-emission tomography to diagnose and stage pancreatic and prostate cancers, tumors in which the GLUT probe 2-[ <jats:sup>18</jats:sup> F]fluoro-2-deoxy- <jats:sc>d</jats:sc> -glucose has questionable utility. Moreover, we suggest, based on our results in mouse models, that Food and Drug Administration-approved SGLT2 inhibitors may be used to reduce the viability of pancreatic and prostate cancer cells in patients. </jats:p>
収録刊行物
-
- Proceedings of the National Academy of Sciences
-
Proceedings of the National Academy of Sciences 112 (30), E4111-, 2015-07-13
Proceedings of the National Academy of Sciences